Eric has a weak
liver.
埃里克的肝脏功能不好。
We like fried goose
liver我们喜欢吃煎的鹅肝。
During the recently concluded sixth China International Import Expo, the company debuted its under-development personalized healthcare solution for liver cancer patients.
在最近结束的第六届中国国际进口博览会上，该公司首次推出了其开发中的癌症患者个性化医疗解决方案。
The solution is designed to improve treatment efficiency and reduce relapse for liver patients in China, a country that has around half of the world's liver cancer cases.
该解决方案旨在提高中国肝脏患者的治疗效率和减少复发，中国的肝癌病例约占世界肝癌病例的一半。
"We'll continue to explore immunotherapy, especially regarding ones with higher prevalence in China, for example, gastric, liver and cellular cancers," she said.
她说：“我们将继续探索免疫疗法，特别是针对中国发病率较高的癌症，例如胃癌、肝癌和细胞癌。”。
Meanwhile, the company is building clinical programs at different stages, targeting gastric and liver cancers, He said.
同时，该公司正在建立不同阶段的临床项目，针对胃癌和肝癌，他说。
"So far, the drug has covered major cancer types, including lymphoma, lung cancer, liver cancer, esophageal cancer and gastric cancer, benefiting millions of Chinese patients," he said.
他说：“到目前为止，该药物已涵盖主要的癌症类型，包括淋巴瘤、癌症、癌症、食管癌症和癌症，使数百万中国患者受益。”。
Starting from the first liver cancer early screening product launched in August 2020, Berry Oncology has built early cancer screening models from multi-omics and multi-dimensional data, which lead to the emergence of the HIFI system.
从2020年8月推出的首款癌症早期筛查产品开始，Berry Oncology从多组学和多维数据构建了癌症早期筛查模型，这导致了HIFI系统的出现。
It has published performance data of early screening with the HIFI system for liver cancer and multiple tumor types that include lung, gastric, colorectal, esophageal and pancreatic cancer.
它已经发表了HIFI系统对癌症和多种肿瘤类型（包括肺癌、胃癌、结直肠癌、食管癌和癌症）进行早期筛查的性能数据。
Sensitivity and specificity of early screening for liver cancer reached 95.42 percent and 97.91 percent respectively, and sensitivity and specificity of early screening for multi tumor types reached 87.58 percent and 99.09 percent, respectively.
癌症早期筛查的敏感性和特异性分别达到95.42%和97.91%，多种肿瘤类型早期筛查的灵敏度和特异性则分别达到87.58%和99.09%。
Meanwhile, Medtronic is exhibiting more than 60 world-class medical technology innovations that cover a wide variety of fields such as heart and blood vessels, innovative surgery, smart medicine, nerve and spine surgery, digestion and liver, kidney health, and critical medicine.
与此同时，美敦力正在展示60多项世界级的医疗技术创新，涵盖心脏和血管、创新外科、智能医学、神经和脊柱外科、消化和肝脏、肾脏健康以及重症医学等广泛领域。
These exhibits will cover seven areas, namely, heart and blood vessels, innovative surgery, smart medicine, nerve and spine surgery, digestion and liver, kidney health, and critical medicine, and will display global medical technology trends of intelligence, digitalization, and minimal invasiveness, said the company.
""As adverse reactions involve various systems in the human body, especially the skin, liver, kidneys and blood, multidisciplinary collaboration within comprehensive hospitals is imperative," deputy head of the Fudan University Shanghai Cancer Center Wu Jiong said.
The patient recruiting platform has helped more than 10 leading pharmaceutical companies, such as Chia Tai Tianqing Pharmaceutical Group and Innovent, to recruit subjects for more than 60 new drug clinical trial projects in areas such as lung cancer, liver cancer, gynecological tumors and gastrointestinal tumors.
The company also reached a series of agreements with local partners in China at the third CIIE, including a contract with domestic health platform JD Health to establish an online liver disease innovation platform that would improve accessibility of the drug Baraclude, which is used to treat hepatitis B infection of the liver.
The partnership encompasses both online and offline components, and focuses on six key areas, which are consumer healthcare, digitization of liver disease management, government medical associations, sharing of customer screening resources, industry and user education, and consolidation of oncology doctors and experts on a single platform.
The first phase of the partnership will focus on liver and lung cancer, Genetron Health said in a press release.
In May and June, the two companies will launch a series of marketing and educational activities for people at high risk of developing liver cancer.
Xin Lijun, senior vice-president of JD and CEO of JD Health, said the two companies will explore the early liver cancer screening field together to enable earlier patient treatment and improve the penetration of liver cancer screening services in the industry.
As every March 18 is National Protect Liver Day in China, to raise awareness of the threat of viral hepatitis and promote early diagnosis and treatment, Gilead Sciences Inc, an internationally leading pharmaceutical company in antiviral solutions, kicked off a large-scale hepatitis C screening campaign on Thursday in China in collaboration with China Liver Health, a non-profit organization promoting liver health.
If they go without timely anti-viral treatment, patients with hepatitis B or C will likely eventually suffer from liver cirrhosis and cancer.
According to the National Cancer Center, the incidence rate of liver cancer among Chinese ranks fourth among all cancers, but its mortality ranks second.
Moreover, more than 92 percent of liver cancer cases progressed from a hepatitis B infection.
According to the agreement, Boston Scientific will transfer TheraSphere Y90 glass microsphere technology to the Chinese company, known as CNRT, for internal radiotherapy of liver cancer, in order to accelerate the introduction and localized production of this medical product to benefit liver cancer patients in China.
"Liver cancer is the fourth most common and the second most deadly malignant tumor seen in China.
Berry Oncology, a subsidiary of China's leading gene sequencing company, announced Monday findings of a clinical research it initiated got published on Cell Research, marking a milestone in its development of a so-called HIFI tumor testing technology used in the research on early detection of liver cancer in cirrhotic patients.
Berry Oncology launched a national project called Precar in 2018, involving multiple centers as China's largest liver cancer screening project for early markers.
The company said its HIFI-empowered product launched in August 2020 for early liver cancer detection can detect early tumorous changes six to 12 months before traditional testing methods, saving valuable time for medical intervention.
The liver cancer early detection product aims at the potential market of China's 90 million hepatitis patients, and about 7 million cirrhosis patients and other high-risk groups.
Li Ning, chief executive officer of Junshi Biosciences, said the company found great unmet medical needs exist in other countries where patients are endangered by this deadly disease, although it prioritizes cancer types with high prevalence in China such as nasopharyngeal carcinoma, lung and liver cancer.
In traditional Chinese medicine, houtougu, or hericium erinaceus, helps digestion by benefiting the five internal organs — heart, liver, spleen, lungs and kidneys.
Gilead is a major US biotechnology company focusing on the development of antiviral medicines effective in the treatment of the HIV, which causes AIDS, and hepatitis, a major liver disease.
The center has a particular vision to discover and develop a cure for hepatitis B as the virus is endemic in China and primary liver cancer caused by HBV has high incidence and mortality rates.
Wuxi Hisky Medical Technologies Co Ltd, a Chinese company leading in the development, manufacture and marketing of high-tech medical equipment for non-invasive liver diagnosis, has launched a new product series called iLivTouch which uses multichannel imaging guided transient elastography.
"Xu Xiaoyuan, director of the infectious disease department of Peking University First Hospital, said the new non-invasive technology allows doctors to easily and accurately detect liver fibrosis and cirrhosis while traditional invasive methods are not always applicable, which is of great significance for the prevention and treatment of liver disease in China.
Jia Jidong, director of the liver disease research center under Beijing Friendship Hospital, Capital Medical University, said the new product can help overcome shortcomings of current clinical practice in liver disease treatment, because it is non-invasive and helps with early detection.
Chinese liver disease patients mostly suffer from viral hepatitis and non-alcoholic fatty liver, but because such diseases have obscure early symptoms, a majority of patients are diagnosed at a late stage, when surgery and drug treatment have limited effects, he said.
Shao Jinhua, CEO of the company, said the new product is based on patented technologies the company and Tsinghua University developed together and can highly improve liver scan accuracy in a user-friendly manner.
In addition to preventing and dealing with gastric cancer, liver cancer and diabetes, people in China should avoid excessive use of antibiotics as it could affect health, she said.
This research group started in 2006 to focus mainly on diseases prevalent in China and Asia, such as liver cancer, gastric cancer, and nasopharyngeal carcinoma, a type of head and neck cancer.
The campus, with more than 700 scientists focusing mainly on research of cancer and liver diseases prevalent in Asia and China, is now playing an increasingly important role in new drug development.
For instance, they will expand the categories of pharmaceutical products they collaborate on for sales and will include drugs for maternal use, while emphasizing treating infant, liver, cancerous, cardiovascular and digestive diseases as cooperation priorities.
"Although there is no permanent treatment for hepatitis B now, with the upgrading of antiviral drugs, chronic hepatitis B patients, who receive long-term treatment, can have better medication options, with a very low drug resistance rate and better safety assurance, reducing the risk of liver cancer," said Ren Hong, head of the Second Affiliated Hospital at Chongqing Medi-cal University.
The company has been developing an immune cell therapy product based on a method called Expanding Activated Lymphocytes to treat solid tumor, and the clinical trial is designed to access the therapy's ability to prevent recurrence after radical surgery of liver cancer, one of the top cancer killers in China.
“Drugs used to treat liver and gastric cancer are considered to be ‘orphan drugs’ in China because such diseases have low incidence rates in other countries and leading pharmaceutical companies would hence spend little to develop them,” she said.
Apart from the treatment of lung cancer, BMS is also exploring immuno-oncology treatments of liver cancer, stomach cancer, esophagus cancer and other high-incidence cancer, Zhao said.
Their aim is to develop the blockchain electronic medical case system to tackle lung cancer and liver diseases.
For example, there is a higher risk of liver cancer in China than in many western countries.
For example, lung cancer, liver disease, upper GI and throat cancer.
These surgical products will be used to treat critical diseases such as lung cancer, liver cancer and gastric cancer.
Laekna Therapeutics, a startup focusing on developing therapies to treat cancer and liver diseases, is expected to submit its first new drug application in the near future in both China and the United States, said Chris Lu, Laekna's founder and CEO.
He gave the example of a medical device proposed by Chinese doctors to improve operations during liver surgery.
"The device was of great value as many suffering from such liver diseases are young and middle-aged people from rural regions.
"We are uncovering the nutritional value of mature vinegar, from basic liver protection to antioxidants, transforming vinegar from a simple seasoning into a healthful and nourishing product," said Zheng Yu, director of the laboratory.
Gilead Sciences, which specializes in developing treatments for human immunodeficiency virus (HIV) and liver diseases such as hepatitis B and C, will participate in the CIIE for the second time this year, according to the company's global vice president Jin Fangqian.
A customer service staff from T-mall told China Securities Journal that the recovery physical exam package pays special attention to the examinations of the lungs, heart, liver and kidneys, which are prone to be attacked by the virus.
Among them are medications for common and chronic diseases such as hypertension, diabetes and digestive disease, as well as serious disorders like lung, liver, kidney and intestinal cancers.
"With one single test, the product can accurately detect six high-risk and high-incidence cancers in China," including lung, esophageal, gastric, liver, pancreatic and colorectal cancers, the company said in a recent statement.
Also, based on the clinical needs of local patients, some clinical trial projects, including innovative therapies for the treatment of solid tumors as well as obesity and fatty liver disease, were already ongoing, he said.
They cover cancers of the lung, liver, stomach and esophagus, which are more common in China.
Founded in August 2017, the company has launched a series of clinical research projects for early screening and diagnosis covering liver, lung, and gynecologic cancers.
In 2018, Berry Oncology launched a national project called PreCar, which is China's largest liver cancer screening project.
The fruit is believed to have health benefits such as protecting the eyes, stabilizing blood sugar levels and preventing liver and kidney damage.
So far a total of 60 customers have made claims as patients suffering from breast cancer, lung cancer, thyroid cancer, prostate cancer, liver cancer, esophageal cancer, gastric cancer and other diseases.
Medlinker has signed a strategic cooperation agreement with Chia Tai Tianqing Pharmaceutical Group to jointly tap potentials in the chronic disease management, including innovative patient care models in sectors such as tumor, liver and respiratory diseases.
"We believe that our model can be especially beneficial to patients suffering from chronic illnesses, such as liver disease, diabetes, cardiovascular and neurodegenerative diseases," he said.
They are big fans of cod liver oil, odorless garlic capsules, grape seed extract capsule, Ginkgo Biloba and Caltrate.
While men were most likely to develop liver cancer, women were most likely to develop breast cancer.
The company he works for has produced more than a dozen prescription dog foods for the China market, aiming to help dogs with illnesses like liver or intestinal problems.
Chinese artificial intelligence pioneer SenseTime unveiled two AI-powered medical solutions for diseases related to the liver and the heart, as the company works hard to harness cutting-edge technologies to help doctors boost efficiency in diagnosis.
SenseTime said the two software solutions are respectively developed to enable faster AI-assisted analysis of Enhanced Liver Computed Tomography and Cardiac Computed Tomography Angiography.
The two solutions are part of applications for SenseTime's SenseCare® Smart Health Platform – an AI-powered platform that offers an array of healthcare applications for over 13 organs and body parts, covering the chest, cardiovascular system, the liver, pathology, orthopedics and radiotherapy.
The company also has a broad development program for tislelizumab that encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkin's lymphoma and UC.